A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Pharmacia and Upjohn32 enrolled

Overview

The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.

Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

HIV Infections

Interventions

Indinavir sulfateDRUG

Delavirdine mesylateDRUG

ZidovudineDRUG

Eligibility

Sex: ALLMin age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml. * Have a CD4 cell count of at least 50 cells/mm3. * Are at least 14 years old (consent of parent or guardian is required if under 18). Exclusion Criteria You will not be eligible for this study if you: * Have ever taken an anti-HIV drug other than ZDV. * Have taken ZDV for more than 1 month.

Locations (6)

AIDS Healthcare Foundation

Los Angeles, California, United States

UCSF AIDS Research Institute

San Francisco, California, United States

Saint Luke's - Roosevelt Hosp Ctr

New York, New York, United States

Anderson Clinical Research

Pittsburgh, Pennsylvania, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.